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Abstract
Background: Thymidine analogues (TA) and didanosine (ddI) are associated with long-lasting adipose tissue
redistribution. Adiponectin is a widely used marker of adipocyte activity, and adipose tissue density assessed by CT-
scan is associated with adipocyte size and function. We hypothesized that prior exposure to TA and ddI was
associated with long-lasting adipose tissue dysfunction in people living with HIV (PLWH). Thus, we tested possible
associations between markers of adipose tissue dysfunction (adipose tissue density and adiponectin) and prior
exposure to TA and/or ddI, years after treatment discontinuation.
Methods: Eight hundred forty-eight PLWH from the COCOMO study were included and stratified according to
prior exposure to TA and/or ddI (with, n = 451; without n = 397). Visceral (VAT) and subcutaneous (SAT) adipose
tissue area and density were determined by single slice abdominal CT-scan at lumbar 4th level. Venous blood was
collected and analyzed for adiponectin. Multivariable linear and logistic regression analyses were used to test our
hypotheses. Multivariable models were adjusted for age, sex, smoking, origin, physical activity, BMI, and adipose
tissue area (VAT or SAT area, accordingly to the outcome).
Results: prior exposure to TA and/or ddI was associated with excess risk of low VAT (adjusted OR (aOR) 1.74 [1.14;
2.67]) and SAT density (aOR 1.74 [1.18; 2.58]), for a given VAT and SAT area, respectively. No association between
VAT and SAT density with time since TA and/or ddI discontinuation was found. 10 HU increase in VAT density was
associated with higher adiponectin plasma level and this association was not modified by prior exposure to TA
and/or ddI. Prior exposure to TA and/or ddI was associated with 9% lower [− 17;-2] plasma adiponectin levels and
with excess risk of low adiponectin (aOR 1.74 [1.10; 2.76]).
Conclusions: We described low adipose tissue density and impaired adiponectin production to be associated with
prior exposure to TA and/or ddI even years after treatment discontinuation and independently of adipose tissue
area. These findings suggest that prior TA and ddI exposure may have long-lasting detrimental effects on adipose
tissue function and, consequently, on cardiometabolic health in PLWH.
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Introduction
Thymidine analogues (TA) and didanosine (ddI) have
known deleterious effect on adipose tissue metabolism
[1]. Previous results from our group suggested that
prior use of TA and ddI in people living with HIV
(PLWH) is associated with alterations in body fat dis-
tribution, particularly loss of subcutaneous (SAT) and
accumulation of visceral adipose tissue (VAT) [1],
even years after treatment discontinuation. This
phenotype is known to be associated with increased
of cardiometabolic risk.
Unfavorable changes in adipose tissue function and
quality accompanies ectopic fat deposition and are
strongly associated with increased incidence of cardio-
vascular diseases in uninfected individuals [2]. Recently,
the association between computed tomography-mea-
sured adipose tissue density (measured in Hounsfield
Units (HU)) and both adipocytes size and function has
been described [3–6]. Low adipose tissue density has
been suggested to indicate adipocyte hypertrophy and is
associated with reduced secretory capabilities, both of
which are considered hallmarks of adipose tissue dys-
function and increased cardiovascular risk [3, 4, 7, 8].
While it was previously only considered an energy
storage, adipose tissue has drawn increasing attention as
endocrine organ and as a fundamental crossway in in-
flammation control [9]. Alterations in plasma levels of
adipokines follows adipose tissue dysfunction, and are
associated with increased cardiovascular risk [3].
Our aim was to investigate if alterations in fat dis-
tributions found in PLWH with prior exposure to TA
and/or ddI are accompanied by long-lasting markers
of adipose tissue dysfunction even years after treat-
ment discontinuation. Previous studies investigating
adipose tissue quality in PLWH have relied on biopsy
and invasive procedures and included a small number
of participants. In the present study, we tested the
hypotheses that: i) for a given VAT and SAT area,
prior use of TA and/or ddI is associated with low
VAT and SAT density, respectively; ii) VAT area and
density are associated with adiponectin plasma levels
and these associations are modified by prior exposure
to TA and/or ddI; iii) for a given VAT area, prior use
of TA and/or ddI is associated with excess risk of low
adiponectin.
Methods
The Copenhagen comorbidity in HIV infection (COCOMO)
study is a longitudinal study with the aim of assessing
the burden of non-AIDS comorbities in PLWH. Of
the 1099 PLWH enrolled in the COCOMO study,
848 PLWH with a CT-scan were included. Procedures
for recruitment and data collection have been de-
scribed in detail elsewhere [10].
Ethical approval was obtained by the Ethics Committee
(H-15017350). Written informed consent was obtained
from all participants.
Clinical assessments
Structured questionnaires were used to collect informa-
tion about demographics, physical activity, and smoking.
Data regarding HIV infection were obtained from review
of medical charts [10].
All physical examinations were performed by clinic
staff as previously described [10].
Outcome definitions
Low adiponectin was defined as having adiponectin
plasma levels in the lowest quartile. Similarly, low VAT
and SAT density were defined as having VAT and SAT
density, respectively, in the lowest quartile.
Blood samples
Non-fasting venous blood was collected and analyzed
for adiponectin at Herlev Hospital, Copenhagen [10].
CT-scan measurement
CT imaging was performed using 320-multidetector scan-
ner (Aquilion One ViSION Edition, Canon, Japan) in a
single rotation (275ms). Field of view (FOV) was 500,
tube voltage was 120 kVp and current was 210mA (inde-
pendent of BMI). For measurement of visceral and sub-
cutaneous adipose tissue, an 8mm section (2 × 4.0 mm)
was reconstructed centered at the level of the 4th lumbar
vertebra. Trained personnel used commercially available
CT software (Fat Measurement, Aquilion ONE; Canon,
Japan) to measure the cross-sectional area of adipose tis-
sue defined as voxels with attenuation values in the range
of − 150 to − 70 Hounsfield units. From within a manually
adjusted region of interest delineated by the muscular
compartments, VAT area was automatically calculated.
SAT was defined as adipose tissue superficial to the ab-
dominal and paraspinal muscles. Intraintestinal and intra-
muscular adipose tissues were manually excluded. Mean
density for VAT and SAT, respectively, were calculated
and reported, using four regions of interest within each fat
depot. All measurements were performed by a single in-
vestigator blinded to stratification status. Intra-reader vari-
ability evaluation showed high intra-reader correlation
(0.975 for VAT density, 0.973 for SAT density) and low
mean intra-reader absolute difference (1.01, SD 0.77 for
VAT density; 1.02, SD 0.99 for SAT density).
Statistical analysis
Continuous variables were reported as median and inter-
quantile range [IQR] and categorical variables as frequency
and percentage (%). Different groups were compared with
t-tests or Mann Whitney U test for continuous data with
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normal or non-normal distribution, respectively, and chi
square/Fisher’s tests for categorical data. In regression ana-
lyses, adiponectin levels were log-transformed.
Associations between prior exposure to TA and/or ddI
and our outcomes were explored with linear or logistic
regression models for continuous or binary outcomes,
respectively. Β coefficients or odds ratio, respectively,
and 95% confidence intervals [CIs] were computed and
reported after adjustment for a base model, which in-
cluded age, sex, smoking, origin, physical activity, BMI,
and fat area (VAT or SAT area, accordingly to the out-
come) as covariates.
Associations between our outcomes and the cumula-
tive period of exposure to and the cumulative time since
discontinuation of TA and/or ddI were explored by add-
ing these covariates into the base model. These analyses
included only individuals with prior exposure to TA
and/or ddI.
Possible interactions of exposure to TA and/or ddI
with VAT area and density, respectively, were tested in
multivariable linear analysis models with plasma adipo-
nectin levels as dependent variable.
Sensitivity analyses considering only individuals > 40
years of age were performed.
Due to log-transformation of plasma adiponectin
levels, regression results regarding this outcome are re-
ported as changes in percentage.
P-values < 0.05 were considered statistically significant.
Statistical analyses were performed using R 3.4.1 (R
Foundation, Austria).
Results
Demographics and HIV-specific characteristics
Eight hundred forty-eight PLWH from the COCOMO
study were included and 451 (53.1%) had current or
prior exposure to TA and/or ddI. Of those, 445 (98.6%)
had only prior exposure, and 6 (1.4%) were still exposed.
The mean cumulative exposure period to TA and/or ddI
was 6.6 (SD, 4.2) years and mean time since discontinu-
ation was 9.4 (SD, 2.7) years. Demographics and HIV-
specific characteristics are depicted in Table 1.
Visceral adipose tissue density
PLWH with exposure to TA and/or ddI had lower VAT
density than PLWH without (− 113.9 [− 115.7 - -109.7]
vs. -108.9 HU [− 113.6 - -104.9], p-value < 0.0001). This
finding was reproduced also after stratification according
to quartiles of VAT (Fig. 1). Prior exposure to TA and/or
ddI was associated excess risk of low VAT density, both
before (crude OR 2.76 [1.97; 3.87]) and after adjusting
for confounders (aOR 1.74 [1.14; 2.67]) (Table 2). This
association was found to be consistent in linear models
(Additional file 1: Table S1). In PLWH with exposure to
TA and/or ddI, no association between VAT density and
either cumulative exposure period to or time since dis-
continuation of these treatments was found (Table 3).
Subcutaneous adipose tissue density
PLWH with exposure to TA and/or ddI had slightly lower
SAT density (− 111.1 HU [− 113.7 - -108.1] vs. -110.4 HU
[− 112.7 - -106.0]; p-value 0.0002). This difference was
more evident in linear regression models after adjusting for,
among the others, SAT area (Additional file 1: Table S1).
Accordingly, prior exposure to TA and/ddI was associated
with excess risk of low SAT density, both before (crude OR
1.61 [1.17; 2.22]) and after adjusting for confounders (aOR
1.74 [1.18; 2.58]) (Table 2). This association was found to
be consistent in linear models (Additional file 1: Table S1).
Longer periods of cumulative exposure to TA and/or ddI
were associated with lower SAT density (Table 3). No asso-
ciation between time since discontinuation of these treat-
ments and SAT density was found (Table 3).
Plasma adiponectin levels
No difference in plasma adiponectin levels and in preva-
lence of low plasma adiponectin was found between
PLWH with and without exposure (Table 1). After
adjusting for confounders, prior exposure to TA and/or
ddI was associated with 9% lower [− 17; − 2] plasma adi-
ponectin levels and with excess risk of low plasma adi-
ponectin (aOR 1.74 [1.10; 2.76]). Borderline interaction
between prior exposure to TA and/or ddI and VAT area
on adiponectin plasma levels was found (p-interaction
0.063).
For a given VAT area, 10 HU increase in VAT density
was associated with 12% [1; 23] and 9% [− 1; 22] higher
plasma adiponectin levels in PLWH with and without
exposure to TA and/or ddI, respectively, even though
not statistically significant in the latter. The association
between VAT density and adiponectin levels was not
modified by prior exposure to TA and/or ddI (p-inter-
action 0.778). No association between SAT density and
plasma adiponectin levels was found in the two groups.
Sensitivity analyses
All results were consistent when limiting the analyses to
participants > 40 years old.
Discussion
In the present study, prior exposure to TA and/or ddI
was associated with excess risk of low adipose tissue
density and low plasma adiponectin irrespective of fat
quantity. These findings suggest that long-lasting alter-
ations of fat distribution previously described in PLWH
with prior exposure to TA and/or ddI [1] are accompan-
ied by markers of adipose tissue dysfunction, even years
after treatment discontinuation.
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TA analogues were among the first antiretroviral treat-
ments introduced to face the HIV epidemic. While ef-
fective in helping to control viral replication, they were
characterized by severe adverse effects on adipose tissue,
whose reversibility is still a subject of debate [1, 11].
While the current use of TA and ddI has declined
worldwide, TA was one of the recommended initial anti-
retroviral treatments until 2005 [12] and any lasting
Table 1 Study groups characteristics
Without exposure to TA and/or ddI (n = 397) With exposure to TA and/or
ddI (n = 451)
p-value
Age, mean (sd) 46.1 (10.5) 55.2 (10.2) < 0.0001
Sex, male, n (%) 361 (90.9) 373 (82.7) 0.0006
Origin, n (%) 0.0497
Scandinavian 274 (70.3) 343 (76.9)
Other EU 49 (12.6) 44 (9.9)
Middle East and Indian subcontinent 13 (3.3) 5 (1.1)
Other 54 (13.8) 54 (12.1)
BMI Categories, n (%) 0.4838
<18.5 9 (2.3) 11 (2.5)
18.5–24.9 211 (53.3) 232 (51.8)
25–29.9 145 (36.6) 156 (34.8)
30 31 (7.8) 49 (10.9)
Smoking status, n (%) < 0.0001
Never smoker 162 (41.8) 136 (30.8)
Current smoker 119 (30.7) 112 (25.3)
Former smoker 107 (27.6) 194 (43.9)
Physical activity, n (%) 0.0709
Very inactive 36 (9.6) 38 (8.8)
Moderately inactive 117 (31.1) 161 (37.4)
Moderately active 161 (42.8) 184 (42.8)
Very active 62 (16.5) 47 (10.9)
Exposure to thymidine analogues and didanosine, n (%) –
Prior exposure – 445 (98.6)
Current exposure – 6 (1.4)
Mode of HIV transmission, n (%) 0.0032
Heterosexual 64 (16.2) 100 (22.4)
IDU 5 (1.3) 5 (1.1)
MSM 311 (78.9) 306 (68.6)
Other 14 (3.6) 35 (7.8)
CD4 nadir < 200 cells, n (%) 89 (23.2) 258 (57.8) < 0.0001
Viral load < 50, n (%) 369 (93.9) 436 (97.1) 0.0357
Current cART, n (%) 397 (100.0) 449 (99.8) 1
VAT area, cm2, median [iqr] 62.3 [32.2, 109.2] 106.5 [55.8, 166.5] < 0.0001
VAT density, HU, median [iqr] -108.9 [− 113.6, − 104.9] − 113.9 [− 115.7, − 109.7] < 0.0001
SAT, cm2,median [iqr] 137.9 [88.6, 198.2] 126.2 [81.2, 177.2] 0.0768
SAT density, HU, median [iqr] − 110.4 [− 112.7, − 106.0] −111.1 [− 113.7, − 108.1] 0.0002
Adiponectin, μg/ml, median [iqr] 11.8 [8.7, 14.7] 11.5 [8.1, 16.3] 0.4822
Low adiponectin, n (%) 74 (23.3) 105 (28.8) 0.1173
Abbreviations: visceral adipose tissue, VAT; subcutaneous adipose tissue, SAT; body mass index, BMI; standard deviations, SD; intravenous drug use, IDU; male-to-
male sex, MSM, combined antiretroviral therapy, cART thymidine nucleoside analog reverse-transcriptase inhibitors, TA; Hounsfield units, HU
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detrimental effects will continue to affect a large propor-
tion of PLWH. Accordingly, increased risk of abdominal
obesity and visceral adipose tissue accumulation has
been recently described in PLWH, especially in those
with prior exposure to TA and/or ddI [1, 13].
The accumulation of adipose tissue can be character-
ized by hyperplasia (increase in number of cells) or
hypertrophy (increase in cell size) [7]. While the former
is accompanied by well-preserved adipocyte function,
adipocyte hypertrophy is associated with increased lipid
content and decreased secretory function [7]. Adipocytes
size is inversely associated with adipose tissue density,
measured by CT-scan [3, 8, 14]. Previous studies de-
scribed lower adipose tissue density to be associated
with adverse cardiovascular risk in uninfected individ-
uals [2, 3, 5, 8]. In the present study, for a given VAT
and SAT area, prior use of TA and/or ddI was associated
with lower adipose tissue density. This finding may
Fig. 1 Comparison of visceral adipose tissue density in people living with HIV with and without prior exposure to TA and/or ddI stratified in
quartiles of VAT. Differences in VAT density between PLWH with and without exposure to TA and/or ddI after stratification of participants
according to quartiles of VAT area. Abbreviations: people living with HIV, PLWH; thymidine nucleoside analog reverse-transcriptase inhibitors, TA;
didanosine, ddI; visceral adipose tissue, VAT; Hounsfield unit, HU; quartiles 1–4, Q1–4
Table 2 Association of prior exposure to TA and/or ddI with low VAT and SAT density
Low visceral adipose tissue density Low subcutaneous adipose tissue density
Crude OR [95% CI] Adjusted OR [95% CI]* Crude OR [95% CI] Adjusted OR [95% CI]**
Prior exposure to TA and/or ddI 2.76 [1.97; 3.87] 1.74 [1.14; 2.67] 1.61 [1.17; 2.22] 1.74 [1.18; 2.58]
Age, per 10 years 1.78 [1.53; 2.07] 1.23 [1.01; 1.50] 1.23 [1.07;1.42] 1.17 [0.98; 1.40]
Sex, male 2.21 [1.25; 3.90] 1.73 [0.84; 3.57] 0.84 [0.53; 1.31] 2.90 [1.57; 5.35]
VAT area, per 50cm2 increase 2.18 [1.91; 2.49] 1.89 [1.59; 2.25] – –
SAT area, per 50cm2 increase – – 1.28 [1.16; 1.42] 2.00 [1.64; 2.43]
Abbreviations: visceral adipose tissue, VAT; subcutaneous adipose tissue, SAT; thymidine nucleoside analog reverse-transcriptase inhibitors, TA; didanosine, ddI.
Multivariable models were adjusted for: age, sex, origin, physical activity, BMI, smoking, VAT* (or SAT**) area, and prior exposure to TA and/or ddI
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suggest that adipocytes hypertrophy, rather than hyper-
plasia, characterizes adipose tissue accumulation in indi-
viduals who had been exposed to these treatments. The
lack of association between adipose tissue density and
time since discontinuation of TA and/or ddI may further
suggest irreversible effect of these treatments on adipose
tissue density, at least in the time-period considered in
the present study.
Mitochondria are fundamental in adipocyte matur-
ation [7]. Mild mitochondrial dysfunction leads to a
moderate increase in reactive oxygen species (ROS) pro-
duction and to reduction in mitochondrial DNA, caus-
ing reactive hypertrophy in the affected adipocytes [7].
We speculate that TA and ddI-associated mitochondrial
toxicity may lead to mild mitochondria dysfunction in
VAT adipocytes, and, consequently, to hypertrophy, that
is present years after treatment discontinuation. This hy-
pothesis is in line with previous studies describing long-
lasting mitochondrial toxicity after TA exposure [15, 16].
Interestingly, in the SAT compartment, we found prior
exposure to TA and/or ddI to be associated with lower
adipose tissue density in the presence of smaller SAT
area compared to those without exposure. We specu-
lated that in SAT, characterized by lower resistance to
mitochondrial toxicity, the same events may lead to se-
vere mitochondrial dysfunction, severe hypertrophy and,
eventually, to the loss of adipocytes [7], which may at
least partly explain the co-presence of low SAT density
and smaller SAT area in PLWH with exposure to TA
and/or ddI.
Reduction in adipose tissue density and mitochondrial
dysfunction are also associated with reduction of adipo-
cytes’ secretory capabilities [6, 17]. Accordingly, in our
population we found a direct association between VAT
density and plasma adiponectin levels. However, this as-
sociation was not modified by prior exposure to TA
and/or ddI. Low plasma adiponectin is associated with
increased systemic inflammation and CVD risk in both
uninfected individuals and PLWH [18]. In particular,
adiponectin has been previously described to have anti-
oxidant, anti-inflammatory properties and to beneficially
affect insulin resistance [19]. In the present study, prior
use of TA and/or ddI was associated with excess risk of
low plasma adiponectin. While the inverse association
between VAT accumulation and adiponectin production
is well-known, we present novel data suggesting that
prior exposure to TA and/or ddI is associated with sig-
nificantly reduced adipocyte secretory capabilities even
in individuals with comparable visceral fat quantity and
years after treatment discontinuation. The interaction
between prior exposure to TA and/or ddI with VAT area
on adiponectin levels, while only borderline significant,
may further suggest a detrimental effect of TA and/or
ddI on adipocyte secretory function following adipose
tissue accumulation.
Taken together our data suggest the potential irreversi-
bility of harmful effects of TA and/or ddI on adipose tis-
sue function, which may negatively affect CVD risk in
PLWH with prior exposure to these treatments. Increas-
ing evidence suggest adipose tissue dysfunction to have a
primary role in the development of CVD through both
direct and indirect mechanisms [8]. Accordingly, dysfunc-
tional adipocytes have been described to promote systemic
inflammation, insulin resistance and atherosclerosis due
to, among the others, reduced production of bioactive
antioxidant and anti-inflammatory adipokines, such as
Table 3 Association between cumulative periods of exposure to and time since discontinuation of TA and ddI with adipose tissue
density
VAT density p-value SAT density p-value
Adjusted β* [95% CI] Adjusted β** [95% CI]
Cumulative time of exposure to TA and/or ddI
<3.6 years Ref Ref
3.6–6.3 years 1.0 [−0.5;2.5] 0.198 −1.0 [−2.4;0.3] 0.141
6.4–9.2 years 0.2 [− 1.3;1.8] 0.770 −2.8 [−4.2;-1.4] < 0.001
>9.2 years − 0.5 [− 2.1;1.2] 0.578 −2.3 [−3.8;-0.9] 0.001
Time since discontinuation of TA and/or ddI
<8.1 years Ref Ref
8.1–9.6 years −0.3 [− 1.8;1.2] 0.702 −0.0 [− 1.4;1.4] 0.965
9.7–10.7 years 1.4 [− 0.1;2.9] 0.074 0.4 [− 1.1;1.8] 0.593
>10.7 0.6 [− 1.0;2.1] 0.460 −0.6 [− 2.0;0.9] 0.431
β coefficients represent the degree of change in HU of VAT and SAT, respectively, associated with each level of the explanatory variables
Abbreviations: visceral adipose tissue, VAT; subcutaneous adipose tissue, SAT; thymidine nucleoside analog reverse-transcriptase inhibitors, TA; confidence
interval, CI
All the models were adjusted for age, sex, origin, physical activity, smoking, BMI, cumulative time of exposure to TA and/or ddI, time since discontinuation of TA
and/or ddI, VAT area* (or SAT area**)
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adiponectin [19], and increased production of pro-throm-
botic molecules [20] and pro-inflammatory cytokines [8].
The present study has several limitations. Due to the
cross-sectional design of the present study, no conclu-
sion on causality can be drawn. Differences in age, sex,
and adipose tissue area between the two groups may ex-
plain part of the findings. However, a possible confound-
ing effect of these variables was reduced by adjusting for,
among the others, age, sex, and adipose tissue area in
multivariable analyses. Finally, the lack of histologic
samples prevented from investigating the association be-
tween cell morphology and CT-findings in the individ-
uals included in the present study and from evaluating
the impact of non-adipocyte cell populations on adipose
tissue density.
Conclusions
In conclusion we described excess risk of low adipose
tissue density and adiponectin production in PLWH
with prior use of TA and/or ddI. These results may sug-
gest that long-lasting adipose tissue dysfunction accom-
panies alterations in fat distribution, even years after TA
and/or ddI discontinuation. Given the central role of
adipose tissue in the regulation of metabolism, cell
morphology and function analyses may be warranted in
order to confirm possible long-lasting detrimental effects
of prior TA and ddI exposure on adipose tissue function
and, consequently, on cardiometabolic health in PLWH.
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Additional file 1: Table S1. Linear Regression Model predicting the
degree of change (with 95% CI) in HU of VAT and SAT density. (DOCX 14 kb)
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